Orphan designation for the company's patented drug, MANF, for Retinitis Pigmentosa expected this week from the European Commission.
Zacks' Senior Bio-Tech Analyst rates it a buy with a valuation four times its current market cap.
$AMGN was under a dime at one point in its history.
Amarantus Bioscience - AMBS - Under a dime.
Zack's Senior Bio-Tech Analyst says it's worth four times the current market cap.
p.s. Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's B.O.D.